Check for updates

OPEN ACCESS

EDITED BY Lukasz Szczerbinski, Broad Institute, United States

REVIEWED BY Nitesh Kuhadiya, Diabetes and Endocrine Center of Nevada (DECON), United States Paresh Dandona, University at Buffalo, United States

*CORRESPONDENCE Xiongfeng Pan, ☑ pxfcsu@163.com Donghai Liu, ☑ liudonghai@csu.edu.cn Xingxing Zhang, ☑ zhangxing@csu.edu.cn

SPECIALTY SECTION This article was submitted to Pharmacoepidemiology, a section of the journal Frontiers in Pharmacology

RECEIVED 22 June 2022 ACCEPTED 31 January 2023 PUBLISHED 16 March 2023

CITATION

Tan X, Pan X, Wu X, Zheng S, Chen Y, Liu D and Zhang X (2023), Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus. *Front. Pharmacol.* 14:975880. doi: 10.3389/fphar.2023.975880

COPYRIGHT

© 2023 Tan, Pan, Wu, Zheng, Chen, Liu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus

Xinrui Tan¹, Xiongfeng Pan²*, Xiaochuan Wu¹, Songjia Zheng¹, Yuyao Chen², Donghai Liu¹* and Xingxing Zhang¹*

¹Department of Pediatrics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China, ²Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, Hunan, China

Background: To assess the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) used as an adjunct to insulin therapy in adults with type 1 diabetes.

Methods: A search of electronic databases (Medline, Embase, and the Cochrane Central Register of Controlled Trials) from 1 January 1950 to 23 May 2021 was conducted to find randomized controlled trials. The primary outcome was the change in HbA1c. Eight efficacy and six safety secondary endpoints were evaluated *via* meta-analysis. Weighted mean difference (WMD) and odds ratio (OR), alongside 95% confidence interval (CI), were calculated using the random effects model.

Results: Among 1,379 candidate studies, 11 trials comprising 2,856 participants satisfied the inclusion criteria. Overall, GLP-1 RA adjunctive therapy reduced HbA1c by -0.21% (95% CI, -0.33 to -0.10), weight by -4.04 kg (-4.8 to -3.27), systolic pressure by -2.57 mmHg (-4.11 to -1.03), and diastolic blood pressure by -1.02 mmHg (-1.99 to -0.06). In addition, there was a decrease in prandial insulin dose (WMD, -4.23 IU; 95% CI, -5.26 to -3.20), basal insulin dose (-2.40 IU; -3.93 to -0.87), and total insulin dose (-5.73 IU; -10.61 to -0.86). Moreover, GLP-1 RAs did not increase the incidence of severe hypoglycemia, diabetic ketoacidosis, or severe adverse events. However, GLP-1 RAs increased the incidence of gastrointestinal adverse events (OR, 2.96; 95% CI, 2.33-3.77).

Conclusion: Our meta-analysis of randomized clinical trials suggests moderate beneficial effects of GLP-1 RAs on the metabolic profile in patients with type 1 diabetes, without an increased risk of serious adverse events.

Clinical Trial Registration: https://www.crd.york.ac.uk/PROSPERO; Identifier: CRD 42020199840.

KEYWORDS

glucagon-like peptide-1 receptor agonists, meta-analysis, type 1 diabetes, adult, adjunctive therapy

Introduction

Type 1 diabetes is characterized by absolute insulin deficiency due to autoimmune destruction. Despite advances in treatments and monitoring methods, less than 20% of patients with type 1 diabetes achieve their glycemic goal (Foster et al., 2019). On the contrary, side effects such as weight gain and hypoglycemic episodes also affect patients' compliance

and confidence in insulin therapy (American Diabetes, 2021). There is much interest in the potential role of non-insulin therapies for type 1 diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as adjuncts to insulin treatment seem to provide a plausible approach to overcome these challenges.

Theoretically, GLP-1 RA and insulin combinational treatment has a good rationale for patients with type 1 diabetes. First, GLP-1 RAs have glucose-lowering effects independent of insulinotropic properties, such as the suppression of glucagon release and the delay of gastric emptying (Andersen et al., 2018). Second, GLP-1 RAs induce satiety by activating the GLP-1 receptor in the brain, leading to bodyweight reduction, which may offset the weight gain associated with insulin therapy (Sandoval and D'Alessio, 2015). Third, due to the wide distribution of GLP-1 receptors, GLP-1 RAs have additional cardioprotective and renal-protective effects, besides its implication on established risk factors (Kristensen et al., 2019). Recently, several clinical trials have been conducted to assess GLP-1 RA and insulin combinational treatment in patients with type 1 diabetes; however, the conclusions of these studies have not been consistent.

Since an individual study may not be sufficient to provide objective evidence, and because GLP-1 RAs differ in structure, size, and pharmacokinetics, including liraglutide, exenatide daily, exenatide extended release (Exenatide ER), and albiglutide, this study carried out an up-to-date meta-analysis to assess this combination therapy in the management of type 1 diabetes. The structures, sizes, and pharmacokinetics of all of the agents are available in Supplementary Material S1.

Methods

Search strategy and selection criteria

Before data extraction, a predetermined detailed analysis protocol was registered in PROSPERO database, registration number CRD 42020199840 (https://www.crd.york.ac.uk/ PROSPERO). The predetermined detailed analysis protocol is available in Supplementary Material S2. This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Experienced librarians designed and adjusted a broad but highly structured MeSH (Medical Subject Headings) terms search strategy. The detailed search strategy for randomized controlled trials that compared GLP-1 RA therapy and placebo in patients with type 1 diabetes is available in Supplementary Material S3. Following PRISMA guidelines, two independent reviewers (Xinrui Tan and Xiongfeng Pan) systematically searched Medline, Embase, and the Cochrane Central Register of Controlled Trials, for randomized controlled trials from 1 January 1950 to 23 May 2021. Disagreements on the eligibility of the studies were settled by involving a third reviewer (Xiaochuan Wu).

Study selection and data extraction

Studies were selected for data extraction based around the PICOS framework: Our population comprised patients with type

1 diabetes (P), the intervention/exposure was GLP-1 RA therapy (I), the comparison was placebo therapy (C), the outcome was change in type 1 diabetes-related efficacy and safety outcomes (O), and the study design included randomized controlled trials (S). Specifically, inclusion criteria were 1) prospective, randomized, and controlled clinical trials; 2) assessment of the efficacy and safety of GLP-1 RAs as an adjunct therapy in patients with type 1 diabetes; 3) at least 8 weeks of intervention. Studies were excluded if they 1) were case reports, retrospective or crossover studies, or conference papers; 2) did not report HbA1c, body weight, or total daily insulin dose at baseline and end of trial; 3) if they included special populations (e.g., individuals with gestational diabetes); or patients with type 2 diabetes. The characteristic data, including the study duration, number of follow-ups, type of GLP-1 RAs used, and outcomes of each trial, were extracted. In order to avoid overlapping populations, this study only analyzed the results with the most comprehensive information. The longest follow-up period to evaluate the main results was used when published studies reported outcomes for various follow-up periods. Two reviewers (Yuyao Chen and Songjia Zheng) independently extracted the data using a custom data extraction template. Disagreements on the eligibility of the studies were settled by involving a third reviewer (Xiaochuan Wu). Endnote (version x9.1) was used to remove duplicate data, and then EpiData (version 3.0) was used to extract data. All the data were stored in a custom Microsoft Excel data extraction template (version 2019).

Outcomes

Outcomes of interest included efficacy variables [HbA1c (%), mean blood glucose (MBG) (mmol/L), glucose SD (mmol/L), mean amplitude of glycemic excursions (MAGE) (mmol/L), body weight (kg), diastolic blood pressure (mmHg), systolic blood pressure (mmHg), total insulin dose (IU), prandial insulin dose (IU), and basal insulin dose (IU)] and safety variables (hypoglycemia, severe hypoglycemia, diabetic ketoacidosis, gastrointestinal disorders, adverse events, severe adverse events). The primary outcomes included HbA1c, MBG, glucose SD, MAGE, hypoglycemia, and severe hypoglycemia; the secondary outcomes included body weight, diastolic blood pressure, systolic blood pressure, total insulin dose, prandial insulin dose, basal insulin dose, diabetic ketoacidosis, gastrointestinal disorders, adverse events, and severe adverse events. Meanwhile, gastrointestinal disorders included nausea, vomiting, and abdominal pain. The definitions of hypoglycemia and severe hypoglycemia were similar to those of the investigated trials and followed the American Diabetes Association criteria (Supplementary Material S4).

Study quality assessment

Two reviewers (Donghai Liu and Xingxing Zhang) independently assessed the eligibility of each trial, extracted data, and evaluated potential bias. The risk of trial bias assessment scheme was used to assess the risk of bias and the quality of the eligible studies as recommended by the Cochrane Collaboration. Any disagreements regarding inclusion were settled by consensus involving a third reviewer (Xinrui Tan).

Statistical analysis

This study used Stata (version 15.0) for the meta-analysis. The weighted mean difference (WMD) and pooled odds ratio (OR) with the corresponding 95% confidence interval (CI) were calculated by random effects inverse variance mode effects meta-analysis (Cohen, 1988; Higgins et al., 2003; Pan, et al., 2020a). WMD was used to evaluate the influence of GLP-1 RAs on HbA1c, MBG, glucose SD, MAGE, body weight, diastolic blood pressure, systolic blood pressure, total insulin dose, prandial insulin dose, basal insulin dose and other markers across the studies (RileyRichard et al., 2011; Michael et al., 2019). The OR was used to evaluate the influence of GLP-1 RAs on hypoglycemia, severe hypoglycemia, diabetic ketoacidosis, gastrointestinal disorders, adverse events, severe adverse events and other safety variables across the studies (Pan, et al., 2020b). Furthermore, this study calculated the inconsistency (I²) to quantify this statistical heterogeneity (Higgins, 2002; DerSimonian and Laird, 2015; Pan et al., 2019). Subgroup meta-analyses were conducted to explore the sources of heterogeneity with respect to the following subgroups based on the sample and study characteristics: The impact of liraglutide in obese and overweight patients versus normal-weight patients, in C-peptide-positive versus negative patients, and long-acting GLP-1 RAs versus short-acting GLP-1 RAs for HbA1c reduction in patients with type 1 diabetes. Lastly, publication bias was estimated visually by funnel plots, and the Egger's test was used to evaluate the possibility of publication bias (Egger et al., 1997). A *p*-value (two-sided) of <0.05 indicates statistically significant results.

Results

The search strategy retrieved a total of 1,379 studies, of which 86 were from PubMed, 1076 from Embase, and 217 from the Cochrane Central Register of Controlled Trials. After excluding duplicate studies, two independent reviewers (Xinrui Tan and Xiongfeng Pan) grouped relevant eligible studies based on title and abstract screening. After excluding duplicate studies, 1,262 abstracts were reviewed, of which 1,206 were excluded. Then, the full texts of the 56 articles were assessed, and it was found that 45 articles (31 with an ineligible study design, three with a short duration of follow-up, eight lacking primary endpoints, and three duplicates) were not eligible for this study and hence were excluded. Disagreements on the eligibility of the studies were settled by involving a third reviewer (Xiaochuan Wu). Finally, 11 randomized trials were included in the final meta-analysis (Supplementary Material S5). All of the trials were published between 2015 and 2021. Eight studies assessed liraglutide, one exenatide daily, one exenatide ER, and one albiglutide. In total, 2856 patients were randomized (2023 to GLP-1 RAs and 833 to placebo) in 11 studies (Table 1).

The mean age of the patients was 43.4 (SD 13.6) years, and 1455 (52%) patients were female. The mean duration of type 1 diabetes

was 22.6 (SD 13.0) years and the duration of the trials ranged from 12 to 52 weeks. The patients' mean HbA1c at baseline was 8.1% (SD 1.0%), while the mean BMI was 29.2 (SD 5.3) kg/m². Six studies enrolled patients using either multiple daily injections (MDIs) or insulin pump (1679 with MDIs and 755 with insulin pump), four trials exclusively enrolled patients using MDIs (302 patients), and the Lira-Pump trial exclusively enrolled patients using insulin pump (44 patients).

Supplementary Material S6 shows the assessment of the quality of the trials according to the Cochrane Handbook for Systematic Reviews of Interventions. All 11 randomized controlled trials reported adequate randomization, allocation concealment, and blinding, and none was stopped early. Three studies had a high risk of incomplete outcome data since a relatively large number of cases were lost during follow-up. One study was classified as high risk in selective reporting because they did not report the outcome of hypoglycemia events. Three studies were considered high risk of other biases because of an imbalanced baseline or inappropriate study design.

Treatment effect

Glycemic efficacy

Pooled analysis showed that GLP-1 receptor agonist adjunctive therapy reduced HbA1c levels compared to the placebo (WMD, -0.21%; 95% CI, -0.33 to -0.10) in patients with type 1 diabetes. Specifically, liraglutide led to a significant reduction in HbA1c (WMD, -0.26%; -0.38 to -0.14), while exenatide, exenatide ER, and albiglutide did not show evident efficacy. This study found no publication bias in this analysis (p = 0.7708).

Regarding mean blood glucose (MBG), pooled analysis showed no difference, but liraglutide reduced MBG by -0.44 mmol/L (95% CI, -0.56 to -0.33) in patients with type 1 diabetes. No difference was found regarding mean glucose SD. Only two studies (Lira-1 and MAG1C) assessed the mean amplitude of glycemic excursions (MAGE) during treatment, and no difference was found (Figure 1).

Insulin dosage

Pooled analysis showed that GLP-1 RAs reduced prandial insulin dose (WMD, -4.23 IU; 95% CI, -5.26 to -3.20), as well as basal insulin dose (-2.40 IU, -3.93 to -0.87) in patients with type 1 diabetes. Notably, liraglutide reduced basal insulin (2.36 IU; -4.20 to -0.51), but exenatide did not show a significant impact. Consistently, the pooled analysis showed that GLP-1 RAs decreased the total insulin dose (-5.73 IU; -10.61 to -0.86). Both liraglutide and exenatide led to significant reductions in the total insulin dose (Figure 2).

Bodyweight

Pooled analysis showed that GLP-1 RAs reduced body weight by 4.04 kg (95% CI, -4.8 to -3.27) in patients with type 1 diabetes. Liraglutide and exenatide reduced body weight by 3.98 kg (-4.54 to -3.44) and 8.3 kg (-13.12 to -3.46), respectively. Albiglutide and exenatide ER did not show favorable effects (Figure 3). This study found no publication bias in this analysis (p = 0.7050).

Study	Treatment	Duration, w	Number of baseline	Number of follow-up	Men, %	Mean age, y	Duration of DM ^a , y	HbA1 ^c , %	BMI ^b , kg/m²	Weight, kg
Kuhadiya et al. (2016)	Liraglutide	12	72	63	44.4	44.8	24.1	7.6	28.8	84.8
Mathieu et al. (2016)	Liraglutide	52	1389	1389	47.7	43.7	21.4	8.2	29.5	86.2
Ahren et al. (2016)	Liraglutide	26	831	831	46.0	43.2	21.1	8.1	28.9	83.9
Dejgaard et al., 2016	Liraglutide	24	100	100	65	48.0	22.5	8.7	30.1	93.7
Johansen et al. 2020	Exenatide	26	108	105	72.4	50.3	21.1	8.3	28.3	87.7
Dejgaard et al. (2021)	Liraglutide	26	44	44	31.8	46.5	20.5	8.2	29.5	86.5
Pozzilli et al. 2020	Albiglutide	52	61	61	55.7	22.5	NA ^c	7.3	22.4	66.8
Frandsen et al. 2015	Liraglutide	12	40	36	66.7	37.8	19.0	8.8	23.5	75.4
Herold et al. 2020	Exenatide er	24	79	79	31.6	36.1	19.6	7.6	29.4	83.9
Ghanim et al. 2020	Liraglutide	26	84	64	37.5	46.2	NA ^c	7.9	31.7	89.6
Brock et al. 2019	Liraglutide	26	48	39	79.5	50.5	31.5	8.2	29.0	92.5

TABLE 1 Characteristics of the trials investigated.

^aDM, diabetes mellitus.

^bBMI, body mass index.

°NA, not available.

Blood pressure

Five trials of liraglutide (n = 340) assessed systolic and diastolic blood pressure during treatment in patients with type 1 diabetes (Figure 3). Liraglutide modestly reduced systolic blood pressure by 2.57 mmHg (95% CI, -4.11 to -1.03) and diastolic blood pressure by 1.02 mmHg (-1.99 to -0.06).

Safety outcomes

Diabetic ketoacidosis

Incidence of diabetic ketoacidosis (DKA) was not increased with GLP-1 adjunctive therapy (OR, 1.38; 95% CI, 0.93–2.05) in patients with type 1 diabetes. Liraglutide did not increase the incidence of DKA (1.37; 0.92–2.03), and no difference was found based on the data from the single trial of exenatide ER (Figure 4A).

Hypoglycemia

GLP-1 adjunctive therapy was associated with a higher risk of hypoglycemia (OR, 1.89; 95% CI, 1.06–3.39) in patients with type 1 diabetes. However, GLP-1 RA therapy did not increase the risk of severe hypoglycemia (0.86; 0.61–1.19). Consistently, respective analyses of liraglutide, exenatide daily, exenatide ER, and albiglutide did not suggest a higher risk of severe hypoglycemia (Figure 4A).

Gastrointestinal disorders

GLP-1 adjunctive therapy significantly increased the incidence of gastrointestinal disorders (OR, 2.96, 95% CI, 2.33–3.77) in patients with type 1 diabetes. Analysis of individual drugs based on the single trial suggested that the incidence of gastrointestinal disorders was higher with liraglutide (2.96; 2.30–3.82) and exenatide ER (4.37; 1.59–12.01) (Figure 4B).

Adverse events

Pooled analysis suggested that GLP-1 RA therapy was associated with a higher risk of adverse events (OR, 2.81; 95% CI, 1.67–4.72) in patients with type 1 diabetes. Liraglutide increased the risk of adverse events (2.88; 1.62–5.12), and the results of exenatide ER from a single trial also showed higher risk (9.50; 1.11–81.67), while albiglutide did not show a significant difference. However, GLP-1 RAs did not increase the incidence of severe adverse events (1.14; 0.73–1.79) in patients with type 1 diabetes. No significant difference was found regarding severe adverse events of liraglutide, albiglutide, or exenatide (Figure 4B).

Subgroup analysis

This study analyzed the impact of liraglutide in obese and overweight patients *versus* normal-weight patients. The HbA1c



Pairwise meta-analysis comparing the glycemic efficacy of GLP-1 RAs therapy for type 1 diabetes. GLP-1 RAs, Glucagon-like peptide-1 receptor agonists; SD, Standard deviation; CL, Confidence interval; MBG, Mean blood glucose; MAGE, Mean amplitude of glycemic excursions.

reduction was -0.43% (95% CI, -0.63 to -0.23) among obese or overweight patients, and -0.10% (-0.63 to 0.43) among normalweight patients. The weight reduction was -6.28 kg (-7.89 to -4.67) among obese or overweight patients, and -4.25 kg (-5.58 to -2.92)among normal-weight patients. Neither subgroup showed a significant effect of liraglutide on severe hypoglycemia. This study also analyzed the impact of liraglutide in C-peptidepositive versus negative patients. The HbA1c reduction amplitude and incidence of DKA was similar in this subgroup analysis. the HbA1c reduction -0.29% (95% Moreover, was

CI, -0.37 to -0.21) with long-acting GLP-1 RA therapy and -0.15% (-0.34 to 0.04) with short-acting GLP-1 RA therapy in patients with type 1 diabetes.

Discussion

In this meta-analysis of 11 up-to-date randomized clinical trials, GLP-1 RA and insulin combination therapy resulted in a modest improvement of metabolic profile, including slight HbA1c reduction, weight loss, a lower insulin dose, and lower blood pressure in patients with type 1 diabetes. Moreover, GLP-1 RAs did not increase the incidence of severe hypoglycemia, diabetic ketoacidosis, or severe adverse events. However, an increased incidence of gastrointestinal events was suggested.

Our meta-analysis showed that GLP-1 RAs modestly but significantly decreased HbA1c levels by 0.21%. In fact, liraglutide is the only GLP-1 RA with improved glycemic control. Seven studies, varying in duration and dosage, assessed liraglutide as an add-on therapy in patients with type 1 diabetes, and three of these trials showed improved glycemic control in patients with combination therapy. Notably, though differing in insulin management strategy, both ADJUNCT ONE and ADJUNCT TWO studies, similarly using 0.6, 1.2, 1.8 mg liraglutide, showed a greater HbA1c reduction at a higher dose during therapy. However, regarding time dependency, the glucose-lowering efficacy initially increased but progressively waned over time in ADJUNCT ONE, ADJUNCT TWO, and Lira-1 studies (Ahrén et al., 2016; Dejgaard et al., 2016; Mathieu et al., 2016). No outcome data were reported about whether the HbA1c reduction would be sustained beyond 1 year of therapy (Doggrell, 2018). Given the chronic course of type 1 diabetes, long-term outcome data of this combination therapy are required.

Thisstudy found that GLP-1 RAs reduced the prandial, basal, and total insulin dose. Findings from Lira-1 and Lira-pump suggest that insulin reduction might be the consequence of weight loss since this effect did not persist after adjusting for bodyweight in patients with type 1 diabetes. On the other hand, GLP-1 RAs increase satiety and decrease food intake, which also affects the bolus insulin dose and postprandial glucose excursions (Dejgaard et al., 2019). Moreover, there might be some different mechanisms for short-acting GLP-1 RAs. In the MAG1c trial, exenatide significantly reduced bolus insulin even after weight adjustment, possibly due to delayed gastric emptying and suppression of postprandial glucagon (Ghazi et al., 2014).

Overall, GLP-1 RAs induced weight loss in patients with type 1 diabetes. GLP-1 RAs counteract insulin-induced weight gain, making combination therapy more beneficial for those patients with obesity (Petrie, 2019). Of note, the result of albiglutide on weight was not directionally concordant with other GLP-1 RAs. It has been proved that the large molecular size of Albiglutide limits its penetration into the brain to induce satiety (Brønden et al., 2017). Our meta-analysis also found that GLP-1 RAs slightly but significantly decreased systolic and diastolic blood pressure. There were doubts about whether this effect is driven by weight loss or is based on the pharmacologic action on GLP-1 receptor blood vessels (Helmstädter et al., 2021). The beneficial effects of GLP-1 RAs on glycemic control, blood pressure, and weight raise the possibility of further cardio-protection (i.e., cardiovascular death,

	Total	RAs Mean	SD	Place Total	bo Mean	n SD	Weighted Mean D	ifference WMD	95% CI	Weight
Exenatide										
Johansen 2020	54 -	8.5 13	.17	54	0.5	17.14		-9.00	[-14.77; -3.23]	3.2%
Random effects model Heterogeneity: not applicable	54			54				-9.00 [-14.77; -3.23]	3.2%
Liraglutide										
Kuhadiya 2016	54 -	5.4 3	.37	18	-1.5	1.65		-3.90	[-5.08; -2.72]	76.4%
Dejgaard 2015	50	0.5 12	.32	50	5.4	12.23		-4.90	[-9.71; -0.09]	4.6%
Dejgaard 2020	22 -	3.1 8	.46	22	3.3	8.12		-6.40	[-11.30; -1.50]	4.4%
Frandsen 2015	20 -	4.0 5	.52	20	0.0	4.24		-4.00	[-7.05; -0.95]	11.4%
Random effects model Heterogeneity: $J^2 = 0\% \tau^2 = 0$	146	70		110				-4.07	[-5.12;-3.03]	96.8%
	o, p = 0.	10		404				4.00		400.00
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$	200 0, <i>p</i> = 0.	44		164		г		-4.23	[-5.26; -3.20]	100.0%
						-1	5 -10 -5 0 5	10 15		
						Favors	treated group Favor	s placebo group		
Basal insulin dose (IU) Study	GLP-1 Total	RAs Mean	SD	Place Tota	ebo I Mear	n SD	Weighted Mean [Difference WMD	95% CI	Weight
,										
Exenatide										
Johansen 2020	54 (0.40 10).27	54	2.5	12.11		-2.10	[-6.34; 2.14]	10.6%
Random effects model Heterogeneity: not applicable	54			54				-2.10	[-6.34; 2.14]	10.6%
Liraglutide										
Kuhadiya 2016	54 -3	3.21 2	2.63	18	0.4	1.65		-3.61	[-4.65; -2.57]	44.0%
Dejgaard 2015	50 3	3.80 16	6.80	50	8.1	16.80		-4.30	[-10.89; 2.29]	4.9%
Dejgaard 2020	22 -1	1.80 3	3.38	22	-0.5	3.16		-1.30	[-3.23; 0.63]	29.3%
Frandsen 2015	20 -0	0.10 6	6.79	20	-0.1	6.36		0.00	[-4.08; 4.08]	11.2%
Random effects model Heterogeneity: $I^2 = 54\%$, $\tau^2 =$	146 = 1.68. p	= 0.09		110			\diamond	-2.36	[-4.20; -0.51]	89.4%
				164						100.0%
Random effects model	200			1 5/1				-2 40		
Random effects model Heterogeneity: $I^2 = 40\%$, $\tau^2 =$	200 = 1.107,	p = 0.1	5	104		1		-2.40	[-3.93; -0.87]	100.070
Random effects model Heterogeneity: $I^2 = 40\%$, $\tau^2 =$	200 = 1.107,	p = 0.1	5	104		-1 Favors	5 -10 -5 0 5 treated group Favor	-2.40 10 15 rs placebo group	[-3.93; -0.87]	100.070
Random effects model Heterogeneity: $I^2 = 40\%$, $\tau^2 =$	200 = 1.107,	p = 0.1	5	Place	ho	- Favors	5 –10 –5 0 5 treated group Favor	-2.40 10 15 rs placebo group	[-3.93; -0.87]	100.070
Random effects model Heterogeneity: $l^2 = 40\%$, $\tau^2 =$ Total insulin dose (IU) Study	200 = 1.107, GLP-1 Total	p = 0.1 RAs Mean	5 SD	Place Total	bo Mean	_^ Favors	5 -10 -5 0 5 treated group Favor	10 15 rs placebo group	95% CI	Weight
Random effects model Heterogeneity: $l^2 = 40\%$, $\tau^2 =$ Total insulin dose (IU) Study	200 = 1.107, GLP-1 Total	p = 0.1 RAs Mean	5 SD 1	Place	bo Mean	Favors	5 -10 -5 0 5 treated group Favor Weighted Mean D	-2.40 10 15 rs placebo group Difference WMD	95% CI	Weight
Random effects model Heterogeneity: $l^2 = 40\%$, $\tau^2 =$ Total insulin dose (IU) Study Liraglutide Kuhadiya 2016	200 = 1.107, GLP-1 Total 54 -8	p = 0.1 RAs Mean	5 SD	Place Total	bo Mean	Favors 5 SD	5 -10 -5 0 5 treated group Favor Weighted Mean D	-6.64	95% CI [-8.46; -4.82]	Weight 25.9%
Random effects model Heterogeneity: / ² = 40%, τ ² = Total insulin dose (IU) Study Liraglutide Kuhadiya 2016 Dejgaard 2015	200 = 1.107, GLP-1 Total 54 -8 50 4	<i>p</i> = 0.1 RAs Mean .54 4. .10 24.	5 SD .63 .90	Place Total	bo Mean -1.90 13.40 3	 Favors 5 SD 2.89 24.90 <	5 -10 -5 0 5 treated group Favor	-2.40 10 15 rs placebo group bifference WMD -6.64 -9.30	95% CI [-8.46; -4.82] [-19.06; 0.46]	25.9%
Random effects model Heterogeneity: / ² = 40%, τ ² = Total insulin dose (IU) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020	200 = 1.107, GLP-1 Total 54 -8 50 4 22 -4	<i>p</i> = 0.1 RAs Mean .10 24. .90 9	5 SD 63 90 47	Place Total	bo Mean -1.90 13.40 2.80	 Favors SD 2.89 24.90 < 8.80	5 -10 -5 0 5 treated group Favor	-2.40 10 15 rs placebo group Difference WMD -6.64 -9.30 -7.70 [95% Cl [-8.46; -4.82] [-19.06; 0.46] -13.10; -2.30]	Weight 25.9% 12.9% 20.2%
Random effects model Heterogeneity: $l^2 = 40\%$, $\tau^2 =$ Total insulin dose (IU) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2015 Dejgaard 2020 Random effects model 1 Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$	200 = 1.107, GLP-1 Total 54 -8 50 4 22 -4 126 0, ρ = 0.3	<i>p</i> = 0.1 RAs Mean .54 4. .10 24. .90 9.	5 SD 63 90 47	Place Total 18 - 50 - 22 90	bo Mean -1.90 13.40 2.80	-1 Favors SD 2.89 24.90 « 8.80	5 -10 -5 0 5 treated group Favor Weighted Mean D	-2.40 10 15 rs placebo group Pifference WMD -6.64 -9.30 -7.70 [-6.82	95% Cl [-8.46; -4.82] [-19.06; 0.46] -13.10; -2.30] [-8.52; -5.13]	Weight 25.9% 12.9% 20.2% 58.9%
Random effects model Heterogeneity: $l^2 = 40\%$, $\tau^2 =$ Total insulin dose (IU) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Random effects model of Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$ Exenatide	200 = 1.107, GLP-1 Total 54 -8 50 4 22 -4 126 0, <i>p</i> = 0.3	p = 0.1 RAs Mean .54 4. .10 24. .90 9.	5 SD .63 .90 .47	Place Total 18 - 50 - 22 90	bo Mean -1.90 13.40 2.80	-1 Favors SD 2.89 24.90 « 8.80	5 -10 -5 0 5 treated group Favor	-2.40 10 15 rs placebo group bifference WMD -6.64 -9.30 -7.70 [-6.82]	95% Cl [-8.46; -4.82] [-19.06; 0.46] -13.10; -2.30] [-8.52; -5.13]	Weight 25.9% 12.9% 20.2% 58.9%
Random effects model Heterogeneity: $l^2 = 40\%$, $\tau^2 =$ Total insulin dose (IU) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Random effects model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$ Exenatide Johansen 2020	300 GLP-1 Total 54 -8 50 4 22 -4 126 5, p = 0.3 54 -7	<i>p</i> = 0.1 RAs Mean .54 4. .10 24. .90 9. 82 .00 23.	5 SD .63 .90 .47 .46	Place Total 18 - 50 - 22 90 54	bo Mean 13.40 2.80	 Favors 5 SD 2.89 24.90 « 8.80	5 -10 -5 0 5 treated group Favor	-2.40 10 15 rs placebo group Difference WMD -6.64 -9.30 -7.70 [-6.82	95% Cl [-8.46; -4.82] [-19.06; 0.46] -13.10; -2.30] [-8.52; -5.13] -17.84; -0.16]	Weight 25.9% 12.9% 20.2% 58.9%
Random effects model Heterogeneity: $l^2 = 40\%$, $\tau^2 =$ Total insulin dose (IU) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Random effects model f Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$ Exenatide Johansen 2020 Random effects model Heterogeneity: not applicable	300 GLP-1 Total 54 -8 50 4 22 -4 126 5, p = 0.3 54 -7 54	<i>p</i> = 0.1 RAs Mean .54 4. .10 24. .90 9. 82 .00 23.	5 SD 63 90 47 46	Place Total 18 - 50 - 22 90 54 54	bo Mean 13.40 2.80	2.89 24.90 < 8.80 23.41 <	5 -10 -5 0 5 treated group Favor	-2.40 10 15 rs placebo group Difference WMD -6.64 -9.30 -7.70 [-6.82] -9.00 [95% CI [-8.46; -4.82] [-19.06; 0.46] -13.10; -2.30] [-8.52; -5.13] -17.84; -0.16] -17.84; -0.16]	Weight 25.9% 12.9% 20.2% 58.9% 14.2%
Random effects model Heterogeneity: $l^2 = 40\%$, $\tau^2 =$ Total insulin dose (IU) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Random effects model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$ Exenatide Johansen 2020 Random effects model Heterogeneity: not applicable	200 = 1.107, GLP-1 Total 54 -8 50 4 22 -4 126 0, p = 0.1 54 -7 54	<i>p</i> = 0.1 RAs Mean .54 4. .10 24. .90 9. 82 .00 23.	5 SD 63 90 47 46	Place Total 18 - 50 - 22 90 54 54	bo Mean -1.90 13.40 2.80 2.00	2.89 24.90 < 8.80 23.41 <	5 -10 -5 0 5 treated group Favor	-2.40 10 15 rs placebo group bifference WMD -6.64 -9.30 -7.70 [-6.82	95% CI [-8.46; -4.82] [-19.06; 0.46] -13.10; -2.30] [-8.52; -5.13] -17.84; -0.16] -17.84; -0.16]	Weight 25.9% 12.9% 20.2% 58.9% 14.2%
Random effects model Heterogeneity: $l^2 = 40\%$, $\tau^2 =$ Total insulin dose (IU) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Random effects model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$ Exenatide Johansen 2020 Random effects model Heterogeneity: not applicable Albiglutide Pozzilli 2020	200 = 1.107, GLP-1 Total 54 - 8 50 4 22 - 4 126 0, p = 0.3 54 - 7 54	p = 0.1 RAs Mean .54 4. .10 24. .90 9. 82 .00 23. .11 0.	5 SD 63 90 47 46	Place Total 18 - 50 - 90 54 54 54 54	bo Mean 13.40 ; 2.80 ; 2.00 ; 0.04	 Favors 2.89 24.90 * 8.80 23.41 * 0.12	5 -10 -5 0 5 treated group Favor	-2.40 10 15 rs placebo group bifference WMD -6.64 -9.30 -7.70 [-6.82] -9.00 [-9.00 [-9.00 [95% CI [-8.46; -4.82] [-19.06; 0.46] -13.10; -2.30] [-8.52; -5.13] -17.84; -0.16] -17.84; -0.16] [-0.05; 0.19]	Weight 25.9% 12.9% 20.2% 58.9% 14.2% 14.2% 26.8%
Random effects model Heterogeneity: $l^2 = 40\%$, $\tau^2 =$ Total insulin dose (IU) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Random effects model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$ Exenatide Dohansen 2020 Random effects model Heterogeneity: not applicable Pozzilli 2020 Random effects model Heterogeneity: not applicable	200 = 1.107, GLP-1 Total 54 -8 50 4 22 -4 126 0, p = 0.3 54 -7 54 15 0 15 0	<i>p</i> = 0.1 RAs Mean .54 4. .10 24. .90 9. 82 .00 23. .11 0.	5 SD 63 90 47 46	Place Total 18 - 50 - 22 90 54 54 54 46 46	bo Mean 13.40 2.80 2.00 3 0.04	-4 Favors 2.89 24.90 < 8.80 23.41 < 0.12	5 -10 -5 0 5 treated group Favor	-2.40 10 15 rs placebo group Difference WMD -6.64 -9.30 -7.70 [-6.82 -9.00 [-9.00 [0.07 0.07	95% CI [-8.46; -4.82] [-19.06; 0.46] -13.10; -2.30] [-8.52; -5.13] -17.84; -0.16] -17.84; -0.16] [-0.05; 0.19] [-0.05; 0.19]	Weight 25.9% 20.2% 58.9% 14.2% 14.2% 26.8%
Random effects model Heterogeneity: $l^2 = 40\%$, $\tau^2 =$ Total insulin dose (IU) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Random effects model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$ Exenatide Johansen 2020 Random effects model Heterogeneity: not applicable Albiglutide Pozzilli 2020 Random effects model Heterogeneity: not applicable Random effects model	200 = 1.107, GLP-1 Total 54 -8 50 4 22 -4 126 0, p = 0.3 54 -7 54 -7 15 0 15	p = 0.1 RAs Mean .54 4 .10 24 .90 9 .82 .00 23 .11 0.	5 SD 63 90 47 46 22	Place Total 18 - 50 - 22 - 90 54 54 54 54 46 46 46	bo Mean 13.40 ; 2.80 2.00 ; 0.04		5 -10 -5 0 5 treated group Favor	-2.40 10 15 rs placebo group bifference WMD -6.64 -9.30 -7.70 [-6.82] -9.00 [-9.00 [0.07 0.07 0.07	95% CI [-8.46; -4.82] [-19.06; 0.46] -13.10; -2.30] [-8.52; -5.13] -17.84; -0.16] -17.84; -0.16] [-0.05; 0.19] [-0.05; 0.19] -10.61; -0.86]	Weight 25.9% 12.9% 20.2% 58.9% 14.2% 14.2% 26.8% 26.8% 26.8%
Random effects model Heterogeneity: $l^2 = 40\%$, $\tau^2 =$ Total insulin dose (IU) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Random effects model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$ Exenatide Johansen 2020 Random effects model Heterogeneity: not applicable Nibiglutide Pozzili 2020 Random effects model Heterogeneity: not applicable Random effects model Heterogeneity: $l^2 = 94\%$, $\tau^2 =$	200 = 1.107, GLP-1 Total 54 -8 50 4 22 -4 126 0, p = 0.3 54 -7 54 15 0 15 15 23.0548	p = 0.1 RAs Mean .54 4. .10 24. .90 9. 82 .00 23. .11 0. .3, $p < 0.$	5 SD 90 47 46 222	Place Total 18 - 50 - 22 90 54 54 54 46 46 46 190	bo Mean 13.40 2.80 2.00 2.00 2.00		5 -10 -5 0 5 treated group Favor	-2.40 10 15 rs placebo group bifference WMD -6.64 -9.30 -7.70 [-6.82 -9.00 [-9.00 [0.07 0.07 0.07 0.07	95% CI [-8.46; -4.82] [-19.06; 0.46] -13.10; -2.30] [-8.52; -5.13] -17.84; -0.16] -17.84; -0.16] [-0.05; 0.19] [-0.05; 0.19] -10.61; -0.86]	Weight 25.9% 12.9% 20.2% 58.9% 14.2% 14.2% 26.8% 26.8% 100.0%

FIGURE 2

Pairwise meta-analysis comparing the insulin dose of GLP-1 RAs therapy for type 1 diabetes. GLP-1 RAs, Glucagon-like peptide-1 receptor agonists; SD, Standard deviation; CL, Confidence interval.

stroke, myocardial infarction, and microvascular complications) in some subgroups of patients with type 1 diabetes (Rawshani et al., 2017; Rawshani et al., 2018). This hypothesis, however, needs further investigation. Our meta-analysis showed that GLP-1 RAs did not increase the risk of diabetic ketoacidosis in patients with type 1 diabetes. SGLT2 inhibitors, another class of anti-diabetic drugs, also once considered to be used as an add-on treatment, were not

Weight (Kg) Study	GLP Tota	P-1 RA al Me	an S	Plac D Tota	ebo I Meai	n SD	Weighted Mean Difference	WMD	95% CI	Weigh
Albiglutide Pozzilli 2020	15	1.63	3.80	46	-0.86	12.69		2.49	[-1.65;	6.63] 3.1
Random effects model Heterogeneity: not applicable	15 9			46				2.49	[-1.65;	6.63] 3.1
Exenatide	54	-6 10	12.84	54	2 20	12 74		-8 30	[-13 12: -	3 481 2 3
Random effects model Heterogeneity: not applicable	54 9	-0.10	12.04	54	2.20	12.74		-8.30	[-13.12; -:	3.48] 2.3
Exenatide ER	40	-2.54	10.29	20	-0.59	10.01		-1.06	[_10.61	6 601 0 9
Random effects model Heterogeneity: not applicable	40 9	2.04	10.20	39	0.00	10.01		-1.96	[-10.61;	6.69] 0.8
Liraglutide Kubadiya 2016	54	-1 23	3 5 8	18	-0.30	2.06		-3.03	[-5 28: -	2 5 81 1/1 8
Mathieu 2016 1	1042	-2 66	4 83	347	0.90	4 47		-3.56	[-4 11 -	3 011 24 0
Ahren 2016	626	-3.85	4.09	206	-0.20	2.30		-3.65	[-4.10: -	3.201 25.0
Deigaard 2015	50	-5.90	13.37	50	0.20	13.37		-6.10	[-11.34; -	0.861 2.0
Dejgaard 2020	22	-6.80	3.04	22	-0.40	2.82		-6.40	[-8.13; -	4.67] 11.4
Frandsen 2015	20	-3.13	2.46	20	1.12	1.78	+	-4.25	[-5.58; -	2.92] 15.0
Ghanim 2020	42	-3.90	18.56	42	0.40	17.93		-4.30	[-12.10;	3.50] 0.9
Brock 2019	28	-4.00	16.81	20	-0.50	16.68		-3.50	[-13.10;	6.10] 0.6
Random effects model 1 Heterogeneity: $I^2 = 36\%$, $\tau^2 =$	1884 = 0.17	29, p =	= 0.14	725				-3.98	[-4.53; -:	3.44] 93.9
Random effects model 1	1993			864			↓	-4.04	[-4.80; -:	3.27] 100.0
Heterogeneity: $I^2 = 57\%$, $\tau^2 =$	= 0.56	06, p ·	< 0.01							
SBP (mmHg) Study	GLP Tota	P-1 RA al Me	s an S	Plac D Tota	ebo I Mear	n SD	Weighted Mean Difference	WMD	95% CI	Weigh
SBP (mmHg) Study Liraglutide	GLP Tota	P-1 RA al Me	s an S	Plac D Tota	ebo IMear	n SD	Weighted Mean Difference	WMD	95% CI	Weigh
SBP (mmHg) Study Liraglutide Kuhadiya 2016	GLP Tota 54	P-1 RA al Me −2.58	us an S 4.16	Plac D Tota 18	ebo IMean −0.5	n SD 2.89	Weighted Mean Difference	WMD -2.08	95% CI [-3.82; -0	Weigh 0.34] 78.8%
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015	GLP Tota 54 50	-1 RA al Me -2.58 -6.00	an S 4.16 15.03	Plac D Tota 18 50	ebo I Mear -0.5 0.0	n SD 2.89 15.83	Weighted Mean Difference	WMD -2.08 -6.00	95% CI [-3.82; -0 [-12.05; 0	Weigh 0.34] 78.8% 0.05] 6.5%
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020	GLP Tota 54 50 22	-1 RA al Me -2.58 -6.00 -6.60	an S 4.16 15.03 13.87	Plac D Tota 18 50 22	ebo I Mear -0.5 0.0 -2.5	2.89 15.83 13.08	Weighted Mean Difference	-2.08 -6.00 -4.10	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3	Weigh 0.34] 78.89 0.05] 6.59 0.87] 3.79
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015	GLP Tota 54 50 22 20	-2.58 -2.58 -6.00 -6.60 -2.30	s an S 4.16 15.03 13.87 10.82	Plac D Tota 18 50 22 20	ebo I Mear -0.5 0.0 -2.5 0.8	2.89 15.83 13.08 9.79	Weighted Mean Difference	-2.08 -6.00 -4.10 -3.10	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3	Weigh 0.34] 78.89 0.05] 6.59 0.87] 3.79 0.29] 5.89
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Bandom effects model	GLP Tota 54 50 22 20 42	-2.58 -6.00 -6.60 -2.30 -5.80	s an S 4.16 15.03 13.87 10.82 18.14	Plac D Tota 18 50 22 20 42	ebo I Mean -0.5 0.0 -2.5 0.8 -1.8	2.89 15.83 13.08 9.79 13.26	Weighted Mean Difference	-2.08 -6.00 -4.10 -3.10 -4.00	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-10.80; 2	Weigh 0.34] 78.89 0.05] 6.59 0.87] 3.79 0.29] 5.89 0.80] 5.19
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$	GLP Tota 54 50 22 20 42 188 0, p =	-2.58 -6.00 -6.60 -2.30 -5.80	s an S 4.16 15.03 13.87 10.82 18.14	Plac D Tota 18 50 22 20 42 152	ebo I Mean −0.5 0.0 −2.5 0.8 −1.8	2.89 15.83 13.08 9.79 13.26	Weighted Mean Difference	-2.08 -6.00 -4.10 -3.10 -4.00 -2.57	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-9.49; 3 [-10.80; 2 [-4.11; -1	Weigh 0.34] 78.89 0.05] 6.59 0.87] 3.79 0.29] 5.89 0.80] 5.19 0.3] 100.09
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$	GLP Tota 54 50 22 20 42 188 0, p = 188	-1 RA al Me -2.58 -6.00 -6.60 -2.30 -5.80 0.76	s 4.16 15.03 13.87 10.82 18.14	Plac Tota 18 50 22 20 42 152 152	-0.5 0.0 -2.5 0.8 -1.8	2.89 15.83 13.08 9.79 13.26	Weighted Mean Difference	-2.08 -6.00 -4.10 -3.10 -4.00 -2.57	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-10.80; 2 [-4.11; -1 [-4.11; -1	Weigh 0.34] 78.89 0.05] 6.59 0.87] 3.79 0.29] 5.89 0.80] 5.19 0.03] 100.09 0.03] 100.09
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$ Random effects model	GLP Tota 54 50 22 20 42 188 0, p = 188 0, p =	-2.58 -6.00 -6.60 -2.30 -5.80 0.76	s 4.16 15.03 13.87 10.82 18.14	Plac Tota 18 50 22 20 42 152 152	-0.5 0.0 -2.5 0.8 -1.8	2.89 15.83 13.08 9.79 13.26	Weighted Mean Difference	••••••••••••••••••••••••••••••••••••••	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-10.80; 2 [-4.11; -1 [-4.11; -1	Weigh 0.34] 78.89 0.05] 6.59 0.87] 3.79 0.29] 5.89 0.80] 5.19 0.03] 100.09 0.03] 100.09
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $J^2 = 0\%$, $\tau^2 = 0$ Random effects model Heterogeneity: $J^2 = 0\%$, $\tau^2 = 0$	GLP 54 50 22 20 42 188 0, p = 188 0, p =	1 RA 2.58 6.00 2.30 5.80 0.76 0.76	s an S 4.16 15.03 13.87 10.82 18.14	Place Place Place	ebo I Mean -0.5 0.0 -2.5 0.8 -1.8	2.89 15.83 13.08 9.79 13.26	Weighted Mean Difference	••••••••••••••••••••••••••••••••••••••	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-10.80; 2 [-4.11; -1 [-4.11; -1	Weigh 0.34] 78.89 0.05] 6.59 0.87] 3.79 0.29] 5.89 0.80] 5.19 0.03] 100.09 0.03] 100.09
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$ Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$	GLP Tota 54 50 22 20 42 188 0, <i>ρ</i> = 188 0, <i>ρ</i> = GLP- Tota	-2.58 -6.00 -6.60 -2.30 0.76 0.76 0.76	an S 4.16 15.03 13.87 10.82 18.14	Place Place Place Place Place	ebo I Mean -0.5 0.0 -2.5 0.8 -1.8	2.89 15.83 13.08 9.79 13.26 Favors	Weighted Mean Difference	-2.08 -6.00 -4.10 -3.10 -2.57 -2.57 group WMD	95% CI [-3.82; -0 [-12.05; C [-12.07; 3 [-9.49; 3 [-4.10; -1 [-4.11; -1 [-4.11; -1	Weigh 0.34] 78.89 0.05] 6.59 0.29] 5.89 0.03] 100.09 0.03] 100.09 Weight
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$ Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$	GLP Tota 54 50 22 20 42 188 0, p = 188 0, p =	-2.58 -6.00 -2.30 -2.30 0.76 0.76	s 4.16 15.03 13.87 10.82 18.14	Place 0 Total 18 50 22 20 42 152 152 152	ebo I Mean −0.5 0.0 −2.5 0.8 −1.8	2.89 15.83 13.08 9.79 13.26 Favors	Weighted Mean Difference	WMD -2.08 -6.00 -4.10 -3.10 -4.00 -2.57 group WMD	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-10.80; 2 [-4.11; -1 [-4.11; -1	Weigh 0.34] 78.89 0.05] 6.59 0.29] 5.89 0.03] 100.09 0.03] 100.09 Weight
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$ Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$ DBP (mmHg) Study Liraglutide Kuhadiya 2016	GLP 54 50 22 20 42 188 0, p = 188 0, p = GLP. Tota	2.58 6.00 2.30 5.80 0.76 0.76 -1 RA: -1 RA: -1 RA: -1 RA: 0.2	s an S 4.16 15.03 13.87 10.82 18.14	Place 18 50 22 20 42 152 152 Place 18 18	ebo I Mean -0.5 0.0 -2.5 0.8 -1.8 bo Mean 0.9	n SD 2.89 15.83 13.08 9.79 13.26 Favors SD 2.06	Weighted Mean Difference	WMD -2.08 -6.00 -4.10 -3.10 -4.00 -2.57 -2.57 group WMD 1.13	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-10.80; 2 [-4.11; -1 [-4.11; -1 95% CI [-2.28; 0.0	Weigh 0.34] 78.89 0.05] 6.59 0.29] 5.89 0.3] 100.09 0.3] 100.09 Weight 02] 70.6%
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$ Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$ DBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015	GLP Tota 54 50 22 20 42 188 0, p = 188 0, p = GLP- Tota 54 54 50 22 20 42 188 0, p = 54 50 50 50 50 50 50 50 50 50 50	-2.58 -6.00 -2.30 -5.80 0.76 0.76 0.76 -1 RA: I Mea	s an S 4.16 15.03 13.87 10.82 18.14 5 n SL 3 2.41 0 8.06	Place Place 18 50 22 20 42 152 152 Place Total 18 50 22 20 42 152	ebo I Mean -0.5 0.0 -2.5 0.8 -1.8 bo Mean 0.9 0.0	n SD 2.89 15.83 13.08 9.79 13.26 Favors SD 2.06 8.80	Weighted Mean Difference	••••••••••••••••••••••••••••••••••••••	95% Cl [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-10.80; 2 [-4.11; -1 [-4.11; -1 95% Cl [-2.28; 0.0 [-4.31; 2.3	Weight 0.34] 78.89 0.05] 6.59 0.87] 3.79 0.29] 5.89 0.3] 100.09 0.03] 100.09 Weight 02] 70.6% 11] 8.5%
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $J^2 = 0\%, \tau^2 = 0$ Random effects model Heterogeneity: $J^2 = 0\%, \tau^2 = 0$ DBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020	GLP Tota 54 50 22 20 42 188 0, p = 188 0, p = GLP- Tota 54 50 22 20 42 188 0, p = 50 50 22 20 42 188 0, p = 50 20 42 188 0, p = 50 188 188 188 198 198 198 198 198	P-1 RA al Me -2.58 -6.00 -2.30 -5.80 0.76 0.76 0.76 -1 RA I Mea -0.22) -1.0 2 -0.7	s an S 4.16 15.03 13.87 10.82 18.14 5 n SE 3 2.41 3 2.41 0 8.06 0 8.06 0 5.64	Place Place Place Place Place Place Place Place Place Place Place Place Place Place Place	ebo I Mean -0.5 0.0 -2.5 0.8 -1.8 bo Mean 0.9 0.0 0.2	n SD 2.89 15.83 13.08 9.79 13.26 Favors SD 2.06 8.80 5.41	Weighted Mean Difference	<pre>wMD -2.08 -6.00 -4.10 -3.10 -4.00 -2.57 -2.57 group wMD 1.13 1.00 0.90</pre>	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-10.80; 2 [-4.11; -1 [-4.11; -1 95% CI [-2.28; 0.0 [-4.31; 2.3 [-4.17; 2.3	Weigh 0.34] 78.89 0.05] 6.59 0.87] 3.79 0.29] 5.89 0.3] 100.09 0.3] 100.09 Weight Weight 02] 70.6% 03] 8.5% 03] 8.7%
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $J^2 = 0\%$, $\tau^2 = 0$ Random effects model Heterogeneity: $J^2 = 0\%$, $\tau^2 = 0$ DBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015	GLP 54 50 22 20 42 188 0, p = 188 0, $p =$ GLP- Tota 54 50 22 20 0 22 20 0 22 20 0 22 20 0 22 20 0 22 20 0 22 20 0 22 20 20	-1 RA al Me -2.58 -6.00 -6.60 -2.30 -5.80 0.76 0.76 0.76 -1 RA: 1 Mea + -0.2) -1.0 2 -0.7) -1.3	s an S 4.16 15.03 13.87 10.82 18.14 3 2.41 3 2.41 3 2.41 0 8.06 0 5.64 0 7.93	Place Place 18 50 22 20 42 152 152 152 Place 18 50 22 20 42 152 152 152 20 152 20 152 20 152 20 152 20 152 152 152 152 152 152 152 152	ebo I Mean -0.5 0.0 -2.5 0.8 -1.8 bo Mean 0.9 0.0 0.2 -0.5	n SD 2.89 15.83 13.08 9.79 13.26 Favors SD 2.06 8.80 5.41 6.16	Weighted Mean Difference	 WMD -2.08 -6.00 -4.10 -3.10 -2.57 -2.57 group WMD 1.13 1.00 0.90 0.80 	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-10.80; 2 [-4.11; -1 [-4.11; -1 [-4.11; -1 [-4.11; -1 [-4.11; -1 [-4.11; 2.3 [-4.17; 2.3 [-4.17; 2.3	Weigh 0.34] 78.89 0.05] 6.59 0.87] 3.79 0.29] 5.89 0.3] 100.09 0.3] 100.09 Weight Weight 02] 70.6% 03] 8.5% 03] 8.7% 03] 4.8%
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2015 Ghanim 2020 Random effects model Heterogeneity: $I^2 = 0\%, \tau^2 = 0$ Random effects model Heterogeneity: $I^2 = 0\%, \tau^2 = 0$ DBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020	GLP Tota 54 50 22 20 42 188 0, $p =$ 188 0, $p =$ Tota GLP- Tota 54 50 22 20 0, $p =$		s 4.16 15.03 13.87 10.82 18.14 3 2.411 0 8.06 0 5.64 0 7.93 0 8.36	Place Place 18 50 22 20 42 152 152 152 Place 18 50 22 20 42 152 152 152	ebo I Mean -0.5 0.0 -2.5 0.8 -1.8 bo Mean 0.9 0.0 0.2 -0.5 -1.7	2.89 15.83 13.08 9.79 13.26 Favors SD 2.06 8.80 5.41 6.16 8.36	Weighted Mean Difference	 WMD -2.08 -6.00 -4.10 -3.10 -2.57 -2.57 group WMD 1.13 1.00 0.90 0.30 0.30 	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-10.80; 2 [-4.11; -1 [-4.11; -1 [-4.11; -1 [-4.11; 2.3 [-4.7; 2.3 [-4.7; 2.3 [-5.20; 3.6 [-3.88; 3.2	Weigh 0.34] 78.89 0.05] 6.59 0.87] 3.79 0.29] 5.89 0.3] 100.09 0.3] 100.09 Weight 02] 70.6% 31] 8.5% 37] 8.7% 30] 4.8% 32] 7.3%
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $I^2 = 0\%, \tau^2 = 0$ DBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $I^2 = 0\%, \tau^2 = 0$	GLP Tota 54 50 22 20 42 188 0, p = 188 0, p = 188 GLP- Tota 54 50 22 20 0, 22 188 = 0, p		s an S 4.16 15.03 13.87 10.82 18.14 3 2.41 0 8.06 0 5.64 0 7.93 0 8.36	Place 18 50 22 20 22 152 152 152 152 152 152 152	ebo I Mean -0.5 0.0 -2.5 0.8 -1.8 bo Mean 0.9 0.0 0.2 -0.5 -1.7	2.89 15.83 13.08 9.79 13.26 Favors SD 2.06 8.80 5.41 6.16 8.36	Weighted Mean Difference	 WMD -2.08 -6.00 -4.10 -3.10 -2.57 -2.57 group WMD 1.13 1.00 0.90 0.80 0.30 1.02 [- 	95% Cl [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-10.80; 2 [-4.11; -1 [-4.11; -1 [-4.11; -1 95% Cl [-2.28; 0.0 [-4.31; 2.3 [-4.17; 2.3 [-4.17; 2.3 [-3.88; 3.2 -1.99; -0.0	Weight 0.34] 78.89 0.05] 6.59 0.87] 3.79 0.29] 5.89 0.3] 100.09 0.3] 100.09 0.3] 100.09 Weight 02] 70.6% 03] 8.5% 03] 8.7% 03] 4.8% 03] 4.8% 03] 4.8%
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2015 Ghanim 2020 Random effects model Heterogeneity: $I^2 = 0\%, \tau^2 = 0$ Random effects model Heterogeneity: $I^2 = 0\%, \tau^2 = 0$ DBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $I^2 = 0\%, \tau^2 = 0$	GLP 54 50 22 20 42 188 0, p = 188 0, p = GLP- Tota 54 50 22 20 42 188 0, p = 188 0, p = 188 188 0, p = 188 188 188 188 188 188 188 18		s 4.16 15.03 13.87 10.82 18.14 3 2.41 0 8.06 0 5.64 0 7.93 0 8.36	Place 18 50 22 200 42 152 152 Place 0 Total 18 50 22 200 42 152 152 152 152 152 152 152 15	ebo I Mean -0.5 0.0 -2.5 0.8 -1.8 bo Mean 0.9 0.0 0.2 -0.5 -1.7	2.89 15.83 13.08 9.79 13.26 Favors 5.41 6.16 8.36	Weighted Mean Difference	 WMD -2.08 -6.00 -4.10 -3.10 -4.00 -2.57 group WMD 1.13 1.00 0.90 0.80 0.30 1.02 [- 1.02 [- 	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-10.80; 2 [-4.11; -1 [-4.11; -1 [-4.11; -1 [-4.11; -1 [-4.11; -1 [-4.11; -1 [-4.11; -1 [-4.11; -1] 95% CI [-2.28; 0.0 [-4.31; 2.3 [-4.17; 2.3 [-4.17; 2.3 [-4.17; 2.3 [-4.38; 3.2 -1.99; -0.0	Weight 0.34] 78.89 0.05] 6.59 0.87] 3.79 0.29] 5.89 0.03] 100.09 0.03] 100.09 0.03] 100.09 Weight 02] 70.6% 03] 8.5% 03] 4.8% 03] 4.8% 03] 4.8% 03] 4.8% 04] 100.0%
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $J^2 = 0\%, \tau^2 = 0$ DBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $J^2 = 0\%, \tau^2 = 0$	GLP- Tota 54 50 22 20 42 188 0, p = 188 GLP- Tota 54 50 22 20 42 188 0, p = 188 0, p = 188 189 0, p = 188 0, p = 188 0, p = 188 0, p = 188 0, p = 188 0, p = 188 189 180 180 180 180 180 180 180 180 180 180		s 4.16 15.03 13.87 10.82 18.14 3 2.41 0 8.06 0 5.64 0 7.93 0 8.36	Place 18 50 22 200 42 152 152 152 18 50 22 200 42 152 152 152 152 152 152 152 15	ebo I Mean -0.5 0.0 -2.5 0.8 -1.8 Mean 0.9 0.0 0.2 -0.5 -1.7	2.89 15.83 13.08 9.79 13.26 Favors 5.06 8.80 5.41 6.16 8.36	Weighted Mean Difference	WMD -2.08 -6.00 -4.10 -3.10 -2.57 -2.57 group 1.13 1.00 0.90 0.80 0.30 1.02 [- 1.02 [-	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-4.11; -1 [-4.11; -1 [-4.11; -1 [-4.11; -1 [-2.28; 0.0 [-4.31; 2.3 [-4.31; 2.3 [-4.31; 2.3 [-4.31; 2.3 [-3.88; 3.2 -1.99; -0.0	Weight 0.34] 78.89 0.05] 6.59 87] 3.79 8.29] 5.89 8.00] 5.19 0.03] 100.09 0.03] 100.09 Weight 02] 70.6% 81] 8.5% 87] 8.7% 03] 4.8% 88] 7.3% 60] 4.8% 88] 7.3% 60] 100.0%
SBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $l^2 = 0\%, \tau^2 = 0$ BBP (mmHg) Study Liraglutide Kuhadiya 2016 Dejgaard 2015 Dejgaard 2015 Dejgaard 2020 Frandsen 2015 Ghanim 2020 Random effects model Heterogeneity: $l^2 = 0\%, \tau^2 = 0$	GLP- Tota 54 50 22 20 42 188 0, p = 188 0, $p =$ 188 54 50 22 20 42 188 54 50 22 20 42 188 80, $p =$ 188 6LP- Tota	P-1 RA al Me -2.58 -6.00 -2.30 -5.80 0.76 0.76 0.76 -1 RA: 1 Mea -0.2 0 -1.0 2 -0.7 0 -1.3 2 -2.0 3 = 1.00	4.16 15.03 13.87 10.82 18.14 3 2.41 0 8.06 0 5.64 0 7.93 0 8.36	Place 18 50 22 200 42 152 152 152 152 18 50 22 200 42 152 152 152 152 152 152 152 15	ebo -0.5 0.0 -2.5 0.8 -1.8 bo Mean 0.9 0.0 0.2 -0.5 -1.7	n SD 2.89 15.83 13.08 9.79 13.26 Favors SD 2.06 8.80 5.41 6.16 8.36	Weighted Mean Difference	 WMD -2.08 -6.00 -4.10 -3.10 -4.00 -2.57 -2.57 group WMD 1.13 1.00 0.90 0.80 0.30 1.02 [- 	95% CI [-3.82; -0 [-12.05; 0 [-12.07; 3 [-9.49; 3 [-10.80; 2 [-4.11; -1 [-4.11; -1 95% CI [-2.28; 0.0 [-4.31; 2.3 [-4.31; 2.3 [-4.17; 2.3 [-5.20; 3.6 [-3.88; 3.2 -1.99; -0.0	Weight 0.34] 78.89 0.05] 6.59 0.29] 5.89 0.3] 100.09 0.3] 100.09 0.3] 100.09 0.3] 100.09 0.3] 100.09 0.3] 100.09 0.3] 100.09 0.3] 70.6% 0.3] 8.5% 0.3] 8.5% 0.3] 8.7% 0.3] 100.0% 0.3] 100.0% 0.3] 100.0%

Pairwise meta-analysis comparing the bodyweight and blood pressure of GLP-1 RAs therapy for type 1 diabetes. GLP-1 RAs, Glucagon-like peptide-1 receptor agonists; SD, Standard deviation; CL, Confidence interval; SBP, Systolic blood pressure; DBP, Diastolic blood pressure.

approved by FDA to be prescribed in patients with type 1 diabetes due to additional ketoacidosis risks (Henry et al., 2015; Garg et al., 2017; Buse et al., 2018; Dandona et al., 2018; Mathieu et al., 2018; Rosenstock et al., 2018; Taylor et al., 2019).

However, the European Commission has authorized dapagliflozin and sotagliflozin as add-on treatments for type 1 diabetes (First oral add-on treatment to insulin for treatment 2019; New add-on treatment to insulin for treatment, 2019).



FIGURE 4

Pairwise meta-analysis comparing the safety of GLP-1 RAs therapy for type 1 diabetes. (A) Pairwise meta-analysis comparing the diabetic ketoacidosis and hypoglycemia of GLP-1 RAs therapy for type 1 diabetes. (B) Pairwise meta-analysis comparing the gastrointestinal disorders and adverse events of GLP-1 RAs therapy for type 1 diabetes. GLP-1 RAs, Glucagon-like peptide-1 receptor agonists; CL, confidence interval.

Clinicians should take careful consideration before combining GLP-1RA with SGLT-2 inhibitor in type 1 diabetes, and intensive monitoring of β -hydroxybutyrate concentrations is highly recommended in these cases (Kuhadiya et al., 2016). Despite the increased risk of hypoglycemia, GLP-1 RAs did not increase the risk of severe hypoglycemia. Similarly, although there were more adverse events for GLP-1 RA combination therapy, the incidence of severe adverse events did not increase. As seen in patients with T2D, GLP-1 RAs increased the incidence of gastrointestinal events (Eng et al., 2014). Taken together, GLP-1 RAs showed a generally safe benefit-to-risk profile in patients with type 1 diabetes.

Obese or overweight versus normal-weight patients merit further discussion. Four studies specified the weight status of the participants, and our meta-analysis suggested that GLP-1

RAs have greater effects on HbA1c and bodyweight reduction in the obese or overweight group. However, a recent post-hoc analysis of ADJUNCT ONE and ADJUNCT TWO suggested that the baseline level of BMI did not impact the safety or efficacy outcomes of liraglutide in type 1 diabetes (Dejgaard et al., 2021). In ADJUNCT ONE trial, insulin adjustment followed the treat-to-target strategy. Namely, the insulin dose was adjusted to reach target postprandial glucose levels. In the ADJUNCT TWO trial, the insulin dose was adjusted within the limits of the insulin cap, which was defined as the average of the previous seven consecutive days' total daily insulin dose. Similarly, both ADJUNCT ONE and ADJUNCT TWO trials reduced 25% of the total daily insulin dose on the day of randomization and a further 10% on subsequent days of liraglutide dose escalation.

Compared with short-acting GLP-1 RAs, our subgroup analysis showed a greater reduction in HbA1c with longacting GLP-1 RAs. Similar findings were also observed in two head-to-head clinical trials in patients with type 2 diabetes (Drucker et al., 2008; Buse et al., 2009). This is likely due to different pharmacokinetic profiles, indicating that sustained GLP-1 receptor activation results in greater suppression of fasting glucagon.

Recently, two network meta-analyses, both including GLP-1 RAs, assessed available antidiabetic medications as an add-on therapy in patients with type 1 diabetes (Kim et al., 2020; Avgerinos et al., 2021). Besides the different analysis methodology and scope, our present pair-wise analysis differed from theirs in the following ways. First, these two studies both included trails shorter than 8 weeks. Our metaanalysis excluded these trails, since such a short duration was not long enough to achieve glycemic steady state. Second, both network analyses included cross-over studies, which may have increased unit-of-analysis errors and bias for carry-over effects. To avoid this, this meta-analysis only included evidence from prospective randomized controlled trials to ensure the quality of the meta-analysis. Third, Ioannis Avgerinos et al. did not include RCTs with albiglutide and exenatide ER, but their conclusion of the main efficacy and safety outcomes was concordant with ours. Yoon Ji Kim et al. involved fewer patients from six studies (four liraglutide and two exenatide) with GLP-1 RAs, and did not detect significant differences regarding HbA1c, insulin dose, and blood pressure.

Several limitations of this analysis should be acknowledged. First, the long-term impact of GLP-1 RAs on patients with type 1 diabetes is unknown; there is no evidence beyond 1 year (Table 1). The effects of GLP-1RA on weight and glycemic control might be mitigated with prolonged therapy. Second, although most of the included studies were of highquality, they carry a potential risk of bias due to pharmaceutical industry funding. Third, the appropriate timing for beginning this combination therapy in the course of type 1 diabetes remains unknown. Recently, two trials suggest that liraglutide preserve beta-cell function in patients with newly diagnosed type 1 diabetes (von Herrath et al., 2021). Therefore, it is speculated that earlier implementation of this combination therapy might be helpful. Given the minor effects of GLP-1 RAs on glycemic control, it is important for clinicians to evaluate the benefits and risks in real-world practice.

Conclusion

In conclusion, our up-to-date meta-analysis suggests modest beneficial effects of GLP-1 RAs on the metabolic profile in patients with type 1 diabetes, without increased risks of DKA, severe hypoglycemia, or severe adverse events. Given the lack of longterm evidence, careful evaluation should be made before prescribing this class of agents in real-world practice.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author contributions

XT and XP contributed to the study design, while YC, SZ, XT, and XP contributed to the data collection. Statistical analyses and interpretation of results were performed by XT, DL, and XZ, whereas YC, XP, and DL drafted the manuscript and edited the language. All the authors participated in the critical revisions, and approved the final version of the manuscript.

Funding

The research is financially supported by the Hunan Natural Science Foundation (No.2019JJ50897) and the Hunan Provincial Key Laboratory of Clinical Epidemiology and the Hunan Provincial Key Research and Development Program (2018SK2065), China.

Acknowledgments

We are grateful to Central South University Library for the assistance during literature search. Furthermore, we sincerely appreciate the hard work of the distinguished editors and reviewers, which improved the clarity of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2023.975880/ full#supplementary-material

References

Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., et al. (2016). Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: The ADJUNCT TWO randomized trial. *Diabetes Care* 39, 1693–1701. Epub 2016/08/06. doi:10.2337/dc16-0690

American Diabetes, A. (2021). 1. Improving care and promoting health in populations: Standards of medical care in diabetes-2021. *Diabetes Care* 44, S7–S14. Epub 2020/12/11. doi:10.2337/dc21-S001

Andersen, A., Lund, A., Knop, F. K., and Vilsbøll, T. (2018). Glucagon-like peptide 1 in health and disease. *Nat. Rev. Endocrinol.* 14, 390–403. doi:10.1038/s41574-018-0016-2

Avgerinos, I., Manolopoulos, A., Michailidis, T., Kitsios, K., Liakos, A., Karagiannis, T., et al. (2021). Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. *Diabetes Obes. Metab. Mar.* 23, 822–831. Epub 2020/12/11. doi:10.1111/dom.14291

Brønden, A., Knop, F. K., and Christensen, M. B. (2017). Clinical pharmacokinetics and pharmacodynamics of albiglutide. *Clin. Pharmacokinet. Jul* 56, 719–731. Epub 2017/01/05. doi:10.1007/s40262-016-0499-8

Buse, J. B., Garg, S. K., Rosenstock, J., Bailey, T. S., Banks, P., Bode, B. W., et al. (2018). Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: The north American inTandem1 study. *Diabetes Care* 41, 1970–1980. Epub 2018/06/26. doi:10.2337/dc18-0343

Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., et al. (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet (London, Engl.* 374, 39–47. Epub 2009/06/12. doi:10.1016/S0140-6736(09)60659-0

Cohen, J. (1988). Statistical power analysis for the behavioral sciences. *Technometrics* 31, 499–500. doi:10.1080/00401706.1989.10488618

Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschöpe, D., Thorén, F., et al. (2018). Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: The DEPICT-1 52-week study. *Diabetes Care* 41, 2552–2559. Epub 2018/10/ 26. doi:10.2337/dc18-1087

Dejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., et al. (2016). Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): A randomised, doubleblind, placebo-controlled trial. *lancet Diabetes & Endocrinol.* 4, 221–232. doi:10.1016/ S2213-8587(15)00436-2

Dejgaard, T. F., Schmidt, S., Frandsen, C. S., Vistisen, D., Madsbad, S., Andersen, H. U., et al. (2019). Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira pump trial - a randomized, double-blinded, placebo-controlled trial. *Diabetes, Obes. metabolism* 22, 492–500. doi:10.1111/dom.13911

Dejgaard, T. F., von Scholten, B. J., Christiansen, E., Kreiner, F. F., Bardtrum, L., von Herrath, M., et al. (2021). Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. *Diabetes Obes. Metab.* 23, 2752–2762. Epub 2021/09/01. doi:10.1111/dom.14532

DerSimonian, R., and Laird, N. (2015). Meta-analysis in clinical trials revisited. *Contemp. Clin. Trials. Nov.* 45, 139–145. Epub 2015/09/08. doi:10.1016/j.cct.2015. 09.002

Doggrell, S. A. (2018). Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes? *Expert Opin. Pharmacother.* 19, 1655–1661. Epub 2018/09/21. doi:10.1080/14656566.2018.1519547

Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., et al. (2008). Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. *Lancet (London, Engl.* 372, 1240–1250. Epub 2008/09/11. doi:10.1016/S0140-6736(08)61206-4

Egger, M., Davey Smith, G., Schneider, M., and Minder, C. (1997). Bias in metaanalysis detected by a simple, graphical test. *BMJ Clin. Res. ed*) 315, 629–634. Epub 1997/10/06. doi:10.1136/bmj.315.7109.629

Eng, C., Kramer, C. K., Zinman, B., and Retnakaran, R. (2014). Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: A systematic review and meta-analysis. *Lancet* 384, 2228–2234. doi:10.1016/ S0140-6736(14)61335-0

First oral add-on treatment to insulin for treatment (2019). First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes. Available at https://www.ema.europa.eu/en/news/first-oral-add-treatment-insulin-treatment-certain-patients-type-1-diabetes.

Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., et al. (2019). State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. *Diabetes Technol. Ther. Feb* 21, 66–72. Epub 2019/01/19. doi:10.1089/dia.2018.0384

Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., et al. (2017). Effects of sotagliflozin added to insulin in patients with type 1 diabetes. *N. Engl. J. Med.* 377, 2337–2348. Epub 2017/09/14. doi:10.1056/NEJMoa1708337

Ghazi, T., Rink, L., Sherr, J. L., and Herold, K. C. (2014). Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. *Diabetes care* 37, 210–216. doi:10.2337/dc13-1169

Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., and Steven, S. (2021). Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor. *Br. J. Pharmacol.* 179, 659–676. Mar 25. Epub 2021/03/ 26. doi:10.1111/bph.15462

Henry, R. R., Thakkar, P., Tong, C., Polidori, D., and Alba, M. (2015). Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. *Diabetes Care* 38, 2258–2265. Epub 2015/10/22. doi:10. 2337/dc15-1730

Higgins, J. P., Thompson, S. G., Deeks, J. J., and Altman, D. G. (2003). Measuring inconsistency in meta-analyses. *BMJ Clin. Res. ed*) 327, 557–560. Epub 2003/09/06. doi:10.1136/bmj.327.7414.557

Higgins, Julian P. T. (2002). Quantifying heterogeneity in a meta-analysis. *Statistics Med.* 11, 1539. doi:10.1002/sim.1186

Kim, Y. J., Hwang, S. D., and Lim, S. (2020). Effects of sodium-glucose cotransporter inhibitor/glucagon-like peptide-1 receptor agonist add-on to insulin therapy on glucose homeostasis and body weight in patients with type 1 diabetes: A network meta-analysis. *Front. Endocrinol. (Lausanne)* 11, 553. Epub 2020/09/26. doi:10.3389/fendo.2020.00553

Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., et al. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. *Lancet Diabetes & Endocrinol.* 7, 776–785. doi:10.1016/S2213-8587(19)30249-9

Kuhadiya, N. D., Ghanim, H., Mehta, A., Garg, M., Khan, S., Hejna, J., et al. (2016). Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. *J. Clin. Endocrinol. Metab.* 101, 3506–3515. Epub 2016/08/05. doi:10.1210/jc.2016-1451

Mathieu, C., Dandona, P., Gillard, P., Senior, P., Hasslacher, C., Araki, E., et al. (2018). Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-Week results from a randomized controlled trial. *Diabetes Care* 41, 1938–1946. Epub 2018/07/22. doi:10.2337/dc18-0623

Mathieu, C., Zinman, B., Ju, Hemmingsson, Woo, V., Colman, P., Christiansen, E., et al. (2016). Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: The ADJUNCT ONE treat-to-target randomized trial. *Diabetes Care* 39, 1702–1710. Epub 2016/08/11. doi:10.2337/dc16-0691

Michael, H., Thornton, S., Xie, M., and Tian, L. (2019). Exact inference on the random-effects model for meta-analyses with few studies. *Biom. Jun* 75, 485–493. Epub 2018/11/16. doi:10.1111/biom.12998

New add-on treatment to insulin for treatment (2019). New add-on treatment to insulin for treatment of certain patients with type 1 diabetes. Available at: https://www.ema.europa.eu/en/news/new-add-treatment-insulin-treatment-certain-patients-type-1-diabetes.

Pan, X., Kaminga, A. C., Chen, J., Luo, M., and Luo, J. (2020a). Fetuin-A and fetuin-B in non-alcoholic fatty liver disease: A meta-analysis and meta-regression. *Int. J. Environ. Res. Public Health* 17, 2735. doi:10.3390/ijerph17082735

Pan, X., Wen, S. W., Bestman, P. L., Kaminga, A. C., Acheampong, K., and Liu, A. (2020b). Fetuin-A in metabolic syndrome: A systematic review and meta-analysis. *PLoS One* 15, e0229776. Epub 2020/03/07. doi:10.1371/journal.pone.0229776

Pan, X., Wu, X., Kaminga, A. C., Wen, S. W., and Liu, A. (2019). Dehydroepiandrosterone and dehydroepiandrosterone sulfate in alzheimer's disease: A systematic review and meta-analysis. *Front. aging Neurosci.* 11, 61. Epub 2019/04/16. doi:10.3389/fnagi.2019.00061

Petrie, J. R. Sattar N. (2019). Excess cardiovascular risk in type 1 diabetes mellitus. *Circ. Feb* 5139, 744–747. Epub 2019/02/05. doi:10.1161/CIRCULATIONAHA.118.038137

Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A. M., Miftaraj, M., et al. (2017). Mortality and cardiovascular disease in type 1 and type 2 diabetes. *N. Engl. J. Med.* 376, 3761407–3761418. Epub 2017/04/14. doi:10.1056/NEJMoa1608664

Rawshani, A., Sattar, N., Franzen, S., Rawshani, A., Hattersley, A. T., Svensson, A. M., et al. (2018). Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: A nationwide, register-based cohort study. *Lancet* (*London, Engl.* 392, 477–486. Epub 2018/08/22. doi:10.1016/S0140-6736(18)31506-X

RileyRichard, D., HigginsJulian, P., Deeks, T., and Jonathan, J. (2011). Interpretation of random effects meta-analyses. *Bmj Br. Med. J.* 342, d549. doi:10.1136/bmj.d549

Rosenstock, J., Marquard, J., Laffel, L. M., Neubacher, D., Kaspers, S., Cherney, D. Z., et al. (2018). Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: The EASE trials. *Diabetes Care* 41, 2560–2569. Epub 2018/10/06. doi:10.2337/dc18-1749

Sandoval, D. A., and D'Alessio, D. A. (2015). Physiology of proglucagon peptides: Role of glucagon and GLP-1 in health and disease. *Physiol. Rev. Apr* 95, 513–548. Epub 2015/04/03. doi:10.1152/physrev.00013.2014

Taylor, S. I., Blau, J. E., Rother, K. I., and Beitelshees, A. L. (2019). SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: Balancing benefits and risks. *Lancet Diabetes & Endocrinol.* 7, 949–958. doi:10.1016/S2213-8587(19)30154-8

von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., et al. (2021). Anti-interleukin-21 antibody and liraglutide for the preservation of β -cell function in adults with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Diabetes & Endocrinol.* 9, 212–224. doi:10.1016/S2213-8587(21)00019-X